5 completed, 3 unknown, 1 enrolling by invitation, 1 recruiting. 11 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Unknown 3, Enrolling by invitation 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Fingolimod: new trials by email Literature Review of Fingolimod trials Research Report on Fingolimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis Ublituximab, Placebo, Fingolimod - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | TG Therapeutics, Inc. | 240 | 2026-07-01 | 2026-10-29 |
| Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage Fingolimod - Intracerebral Hemorrhage | Phase 1 / Phase 2 | Unknown | Tang-Du Hospital | 40 | 2023-10-11 | 2023-10-18 |
| Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Fingolimod, Placebo - Interstitial Fibrosis, Kidney Transplant; Complications | Phase 2 | Enrolling by invitation | The Methodist Hospital Research Institute | 20 | 2022-07-28 | 2025-03-14 |
| Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke Fingolimod, Placebo - Stroke, Inflammation | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 118 | 2021-01-15 | 2023-04-18 |
| Fingolimod in Endovascular Treatment of Ischemic Stroke Fingolimod - Stroke Inflammation | Phase 2 | Unknown | Ning Wang, MD., PhD. | 30 | 2020-11-12 | 2022-04-13 |
| Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke Fingolimod - Stroke, Inflammation | Phase 2 | Withdrawn | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2016-11-01 | 2021-07-22 | |
| Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients Fingolimod, Fish Oil, Placebo (for Fish Oil) - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Isfahan University of Medical Sciences | 50 | 2015-04-01 | 2019-05-14 |
| Gilenya in Amyotrophic Lateral Sclerosis (ALS) Gilenya, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Massachusetts General Hospital | 30 | 2013-08-01 | 2016-07-01 |
| Fingolimod in Schizophrenia Patients Fingolimod, placebo - Schizophrenia | Phase 2 | Completed | Indiana University | 40 | 2013-01-01 | 2019-04-16 |
| Efficacy and Safety of FTY720 for Acute Stroke Fingolimod - Stroke, Vascular Accident | Phase 2 | Completed | Tianjin Medical University General Hospital | 22 | 2012-10-01 | 2018-10-17 |
| An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis Fingolimod - Multiple Sclerosis | Phase 2 | Completed | Novartis | 143 | 2008-04-01 | 2013-09-04 |
Ischemic Stroke (3) · Stroke (3) · Inflammation (2) · Multiple Sclerosis (2) · Amyotrophic Lateral Sclerosis (1) · Cerebral Hemorrhage (1) · Fibrosis (1) · Kidney Failure, Chronic (1) · Psychotic Disorders (1) · Pulmonary Fibrosis (1) · Rejection, Psychology (1) · Schizophrenia (1)
Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Indiana University (1) · Isfahan University of Medical Sciences (1) · Massachusetts General Hospital (1) · Ning Wang, MD., PhD. (1) · Novartis (1) · TG Therapeutics, Inc. (1) · Tang-Du Hospital (1) · The Methodist Hospital Research Institute (1) · Tianjin Medical University General Hospital (1)
China (4) · United States (4) · Japan (1) · Poland (1) · Slovakia (1)
Alan Breier, MD (1) · Fu-Dong Shi, MD,PhD (1) · James D Berry, MD, MPH (1) · Michael Francis, MD (1) · Min Lou, MD,PhD (1) · Min Lou, PhD, MD (1) · Shaygannejad Shaygannejad, M.D. (1) · Yan Qu (1)
PMID 24475777, PMID 25003359, PMID 26202811, PMID 28129749, PMID 35720286
2025 (1)